Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand to Report Second Quarter 2018 Results on August 6th

Read More

Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement

Read More

Ligand Prices Offering of $650 Million of Convertible Senior Notes

Read More

Recent Events

Upcoming Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range